Let lung cancer patients “live well and live long”! For lung cancer patients, when they are first diagnosed, it is like a bolt from the blue. Patients and their families will try their best to receive treatment and destroy the tumor. In fact, lung cancer is its own long-term chronic pathological product. Effective treatments such as surgery, chemotherapy and radiotherapy may not necessarily eliminate all the cancer cells, but what should be more concerned is the patient’s survival quality and overall recovery. Although many patients have their lung tumors completely removed or shrunk, many of them feel that “life is worse than death” because of the side effects of treatment. Therefore, in the post-surgical treatment of lung cancer, the core of post-surgical treatment has been to improve the immunity of patients and to enhance and improve the quality of survival, that is, to let lung cancer patients not only live, but also to live with quality, or as we often say, “live well”. For decades, there are three main treatments for lung cancer and other malignant tumors: surgical treatment, chemotherapy and radiotherapy. Some people once called this iron triangle therapy as “sharp knife, poison and branding iron”. These three treatments mainly focus on tumor destruction or tumor suppression, but their toxic side effects are also very great. Often the lung tumor becomes smaller or disappears, but the quality of life is reduced and the life span is not prolonged. For example, although small cell lung cancer tumors are easier to eliminate, patients’ life span is not necessarily prolonged; low-grade malignant tumors, however, can survive with tumors for a long time. Especially some elderly patients, whose organ functions are weaker and combined with other chronic diseases, often shorten their survival time due to severe toxic side effects if they are treated with excessive aggressive treatment. Therefore, if aggressive treatment is applied to patients with poor physical condition and relatively large tumor load, it may result in the death of cancer cells and patients’ lives. Therefore, for patients with intermediate or advanced tumors, aggressive treatments that do not definitely prolong life should be treated with caution; for some patients who do not have indications for radiotherapy or chemotherapy again, the effect of pursuing local tumor regression without taking into account the systemic situation is often counterproductive. There was a patient with advanced lung cancer combined with pleural fluid and small amount of pericardial effusion, who was in poor general health condition and suffered from coronary heart disease and diabetes, so it was not suitable for systemic chemotherapy according to common sense. As a result, the pleural fluid was significantly controlled and the primary lesion in the lung did not increase in size. After adjusting the treatment for more than 3 years, the patient’s general condition was good and the pleural fluid was stable, but the intrapulmonary lesions were slightly larger than before. At this point, the patient and his family were not willing to “sit and wait for death”, and they strongly requested the application of systemic chemotherapy in order to control the development of the lesions and prepare for a “back-to-back battle”. So they went to another hospital for two cycles of chemotherapy. After chemotherapy, the tumor lesions did not shrink significantly, but the patient’s physical condition deteriorated sharply, with symptoms such as chest tightness and dyspnea significantly aggravated, and serious lung infection appeared, and he died in less than a month. So, how to achieve both treating the disease and improving the quality of life of patients? The current fourth treatment method of tumor, immunotherapy, has solved this problem for the majority of tumor patients. Immunotherapy methods include mature methods that have been clinically proven to be really effective in Chinese and Western medicine treatment to improve patients’ immunity. For patients who are not in good health and cannot bear the side effects of surgery and radiotherapy, or whose body condition becomes worse after these treatments, immunotherapy can improve the immunity of the body, restore the immune damage caused by surgery and traditional radiotherapy, relieve the symptoms of patients and improve the quality of life of patients, so as to achieve the goal of “living well”. The purpose of “living well” is to improve the immune system, restore the immune damage caused by surgery and traditional radiotherapy, relieve the patient’s symptoms, and improve the patient’s quality of life. ”Living well” is the goal of tumor patients, but not the final goal. The final goal is “living long”. Many patients neglect the late treatment once their disease is stabilized and they enter the recovery period. In a questionnaire, when asked what they want to do after being discharged from the hospital, many tumor patients blankly filled in the word “nothing”, in fact, they really did not think of special treatment in the recovery stage, thinking that everything would be fine after entering the recovery period. According to incomplete statistics, 40% of the per capita medical expenses of tumor patients are spent in the last year of life, and 40% of them are spent in the last month of life. 80% of tumor patients die not in the treatment period, but in the recovery period. Therefore, tumor patients should not relax their vigilance even when they enter the recovery period, and must establish the idea of lifelong “second treatment”, that is, treatment during the recovery period, so that they can “live longer”. For lung cancer patients, conventional treatments such as surgery, radiotherapy and chemotherapy are necessary, but far from the end, because the aggressive “first treatment” can at best only “reduce” or inhibit tumor, but cannot completely destroy it, let alone change the internal environment that makes tumor occur and develop. Therefore, it leaves a hidden danger for the metastasis and recurrence of tumor. Focusing on the “second treatment” of overall rehabilitation, adjusting and restoring the traumatized physiological functions, especially the immune function, and changing the small environment in the body that is conducive to tumor growth, can effectively prevent tumor recurrence, metastasis and regeneration. For lung cancer patients, the “second treatment” can be said to be lifelong, or at least must be experienced for more than years to achieve the three major goals of ideal recovery before drawing a conclusion temporarily. In fact, it is not uncommon for many patients to see the tumor again 20-30 years later after recovery. It is very important to establish the idea of lifelong “second treatment” to effectively reduce the recurrence rate and metastasis rate of tumor, prolong the survival time of patients and improve their quality of life. So, how to carry out “second treatment”? After treatment, tumor patients enter the recovery period, but some of them have residual tumor cells or microscopic tumor cells in their bodies, and tumor patients are generally weak, or their immunity decreases due to the previous treatment, so they are unable to remove these residual tumor cells, which leads to tumor recurrence and metastasis, resulting in many patients dying in the recovery period. Therefore, in the treatment of recovery period, it is very crucial to improve the immunity of the body. The fourth treatment method of tumor, immunotherapy, solves this problem again. Immunotherapy can improve body immunity, effectively remove residual tumor cells, prevent metastasis and recurrence of tumor, and thus prolong survival period. During the recovery period of tumor, regular immunotherapy can significantly extend the survival period of patients, thus realizing the goal of “living longer” for lung cancer patients. Therefore, lung cancer is not a terrible disease, as long as the patient is treated reasonably during the disease and recovery period, lung cancer patients can achieve the goal of “living well and living long”.